CoChat
Sign Up
Cited by 148

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways

Xu, Yanmin, Huang, Ji, Ma, Leina, Shan, Juanjuan, Shen, Junjie, Yang, Zhi, Liu, Limei, Luo, Yongli, Yao, Chao, Qian, Cheng·2016·Cancer Letters
DOI 10.1016/j.canlet.2015.11.034
Open this paper in CoChat — free account

Abstract

Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. In this study, we investigated the molecular mechanisms of sorafenib resistance in HCC cells. Our miRNA microarray data indicate that liver-specific miR-122 expression was significantly reduced in sorafenib-resistant cells. Overexpression of miR-122 made drug-tolerant cells sensitive to sorafenib and induced apoptosis. Insulin-like growth factor 1 receptor (IGF-1R) was validated as a target of miR-122 and was repressed by this miRNA. miR-122-induced apoptosis was repressed by the IGF-1R activator IGFI or IGFII. Conversely, the IGF-1R inhibitor PPP or NVP-AEW541 in combination with sorafenib significantly induced cell apoptosis and disrupted tolerance to drugs in vitro. These results indicated that activation of IGF-1R by ectopic down-regulation of miR-122 counteracted the effects of sorafenib-induced apoptosis, thus conferring sorafenib resistance. Further study revealed that activation of IGF-1R by miR-122 down-regulation contributed to activation of RAS/RAF/ERK signaling, which was associated with drug resistance. Our data imply that an intimate correlation between miR-122 and IGF-1R abnormal expression is a critical determinant of sorafenib tolerance.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2015.11.034

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 39

  1. Bruix, 2003, HCC surveillance: who is the target population?, Hepatology, 37, 507, 10.1053/jhep.2003.50142 · DOI
  2. Huo, 2005, Comparison of staging systems for HCC: one more positive answer or mission impossible?, Hepatology, 42, 238, 10.1002/hep.20758 · DOI
  3. Villanueva, 2010, Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy, Annu. Rev. Med, 61, 317, 10.1146/annurev.med.080608.100623 · DOI
  4. Vitale, 2010, Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety, Hepatology, 51, 165, 10.1002/hep.23260 · DOI
  5. Shen, 2010, Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives, J. Gastroenterol, 45, 794, 10.1007/s00535-010-0270-0 · DOI
  6. Johnson, 2009, Sorafenib for liver cancer: the horizon broadens, Lancet Oncol, 10, 4, 10.1016/S1470-2045(08)70317-6 · DOI
  7. Tejeda-Maldonado, 2015, Diagnosis and treatment of hepatocellular carcinoma: an update, World J. Hepatol, 7, 362, 10.4254/wjh.v7.i3.362 · DOI
  8. Villanueva, 2012, Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib, Clin. Cancer Res, 18, 1824, 10.1158/1078-0432.CCR-12-0151 · DOI
  9. Xin, 2013, Label-retaining liver cancer cells are relatively resistant to sorafenib, Gut, 62, 1777, 10.1136/gutjnl-2012-303261 · DOI
  10. Berasain, 2013, Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?, Gut, 62, 1674, 10.1136/gutjnl-2013-304564 · DOI
  11. Engelman, 2008, Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer, Clin. Cancer Res, 14, 2895, 10.1158/1078-0432.CCR-07-2248 · DOI
  12. Ryu, 2015, Human genes with a greater number of transcript variants tend to show biological features of housekeeping and essential genes, Mol. Biosyst, 11, 2798, 10.1039/C5MB00322A · DOI
  13. Davidson-Moncada, 2010, MicroRNAs of the immune system: roles in inflammation and cancer, Ann. N. Y. Acad. Sci, 1183, 183, 10.1111/j.1749-6632.2009.05121.x · DOI
  14. Shenouda, 2009, MicroRNA function in cancer: oncogene or a tumor suppressor?, Cancer Metastasis Rev, 28, 369, 10.1007/s10555-009-9188-5 · DOI
  15. Rao, 2010, MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways, Oncogene, 30, 1082, 10.1038/onc.2010.487 · DOI
  16. Liu, 2014, miR222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma, Int. J. Oncol, 45, 1537, 10.3892/ijo.2014.2577 · DOI
  17. Song, 2014, miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting p-type adenosine triphosphatase A (ATP7A), J. Cell. Biochem, 115, 1234, 10.1002/jcb.24665 · DOI
  18. Mao, 2014, Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib, Cancer Lett, 352, 245, 10.1016/j.canlet.2014.07.004 · DOI
  19. Chang, 2008, Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells, J. Virol, 82, 8215, 10.1128/JVI.02575-07 · DOI
  20. Blanc, 2014, Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver, Genome Biol, 15, R79, 10.1186/gb-2014-15-6-r79 · DOI
  21. Kutay, 2006, Downregulation of miR-122 in the rodent and human hepatocellular carcinomas, J. Cell. Biochem, 99, 671, 10.1002/jcb.20982 · DOI · Paper page
  22. Xu, 2010, Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development, Hepatology, 52, 1431, 10.1002/hep.23818 · DOI
  23. Tsai, 2009, MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma, Hepatology, 49, 1571, 10.1002/hep.22806 · DOI
  24. Coulouarn, 2009, Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties, Oncogene, 28, 3526, 10.1038/onc.2009.211 · DOI
  25. Xu, 2011, MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest, Cancer Lett, 310, 160
  26. Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69, 10.1016/j.cell.2010.02.027 · DOI · Paper page
  27. Villanueva, 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, 18, 683, 10.1016/j.ccr.2010.11.023 · DOI
  28. Cortés-Sempere, 2013, IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer, Oncogene, 32, 1274, 10.1038/onc.2012.146 · DOI
  29. Ma, 2010, Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells, Cancer Biol. Ther, 9, 554, 10.4161/cbt.9.7.11267 · DOI
  30. Casa, 2008, The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance, Front. Biosci, 13, 3273, 10.2741/2925 · DOI
  31. Tao, 2007, Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway – therapeutic perspectives in cancer, Nat. Clin. Pract. Oncol, 4, 591, 10.1038/ncponc0934 · DOI
  32. Wan, 2007, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism, Oncogene, 26, 1932, 10.1038/sj.onc.1209990 · DOI
  33. Navarro, 2001, Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor, Endocrinology, 142, 1073, 10.1210/endo.142.3.7991 · DOI
  34. Rahman, 2015, Cancer metabolism and drug resistance, Metabolites, 5, 571, 10.3390/metabo5040571 · DOI
  35. Spinzi, 2008, Sorafenib in advanced hepatocellular carcinoma, N. Engl. J. Med, 359, 2497, 10.1056/NEJMc081780 · DOI
  36. Kurata, 2004, Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance, Ann. Oncol, 15, 173, 10.1093/annonc/mdh006 · DOI
  37. Moriceau, 2015, Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction, Cancer Cell, 27, 240, 10.1016/j.ccell.2014.11.018 · DOI
  38. Dallas, 2009, Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition, Cancer Res, 69, 1951, 10.1158/0008-5472.CAN-08-2023 · DOI
  39. Morgillo, 2011, Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors, Br. J. Cancer, 105, 382, 10.1038/bjc.2011.244 · DOI

Cited by

Sorted by citations

See all 148

Metadata

Authors
Xu, Y., Huang, J., Ma, L., Shan, J., Shen, J., Yang, Z., Liu, L., Luo, Y., Yao, C., & Qian, C.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2016-02
Volume
371
Issue
2
Pages
171-181
ISSN
0304-3835
DOI
10.1016/j.canlet.2015.11.034
Cited by
148
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
National Natural Science Foundation of China (81330048, 81520108025, 81301864, 81472292, 81572464)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review